1. Home
  2. NVNO vs PULM Comparison

NVNO vs PULM Comparison

Compare NVNO & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo enVVeno Medical Corporation

NVNO

enVVeno Medical Corporation

N/A

Current Price

$6.15

Market Cap

6.1M

Sector

Health Care

ML Signal

N/A

Logo Pulmatrix Inc.

PULM

Pulmatrix Inc.

N/A

Current Price

$1.30

Market Cap

5.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NVNO
PULM
Founded
1987
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1M
5.2M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
NVNO
PULM
Price
$6.15
$1.30
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 33.8K
31.9K
Earning Date
10-29-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 46.18
EPS
N/A
★ N/A
Revenue
$31,243.00
★ $7,910,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$67.27
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 5069.93
52 Week Low
$0.30
$1.06
52 Week High
$13.44
$4.98

Technical Indicators

Market Signals
Indicator
NVNO
PULM
Relative Strength Index (RSI) 37.92 39.26
Support Level N/A $1.18
Resistance Level $11.47 $1.50
Average True Range (ATR) 0.59 0.15
MACD 0.04 -0.01
Stochastic Oscillator 12.16 43.00

Price Performance

Historical Comparison
NVNO
PULM

About NVNO enVVeno Medical Corporation

enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.

About PULM Pulmatrix Inc.

Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

Share on Social Networks: